Moleculin reports preliminary blinded CR rate ~30% in MIRACLE trial; first unblinding before June 30

Moleculin Biotech, Inc.

Preliminary blinded CRc >40%, CR ~30% vs. historical ~17-18% for cytarabine alone.
First unblinding of 45-subject data expected before June 30, 2026; ~30 Annamycin + cytarabine vs 15 control.
56 of 90 subjects recruited in Part A as of May 1, 2026; on track for Q3 2026 completion.
Over 30% of subjects are R/R to prior venetoclax regimen, a challenging population.
Annamycin has FDA Fast Track and Orphan Drug Designations for R/R AML.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.